MX2018007933A - Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina. - Google Patents
Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.Info
- Publication number
- MX2018007933A MX2018007933A MX2018007933A MX2018007933A MX2018007933A MX 2018007933 A MX2018007933 A MX 2018007933A MX 2018007933 A MX2018007933 A MX 2018007933A MX 2018007933 A MX2018007933 A MX 2018007933A MX 2018007933 A MX2018007933 A MX 2018007933A
- Authority
- MX
- Mexico
- Prior art keywords
- mammal
- treating
- methionine
- including human
- against cancer
- Prior art date
Links
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229930182817 methionine Natural products 0.000 title abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 title 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 title 1
- 229960001230 asparagine Drugs 0.000 title 1
- 235000009582 asparagine Nutrition 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000015790 Asparaginase Human genes 0.000 abstract 3
- 108010024976 Asparaginase Proteins 0.000 abstract 3
- 108010043135 L-methionine gamma-lyase Proteins 0.000 abstract 3
- 229960003272 asparaginase Drugs 0.000 abstract 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 abstract 3
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y404/00—Carbon-sulfur lyases (4.4)
- C12Y404/01—Carbon-sulfur lyases (4.4.1)
- C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere a un nuevo método para tratar cánceres líquidos y sólidos, en un mamífero, que incluye el ser humano, en donde la metioninasa se administra antes que la asparaginasa. La invención también abarca el uso de una privación de metionina dietética, posiblemente combinada con administración de metioninasa, antes del tratamiento con asparaginasa. La metioninasa y la asparaginasa pueden usarse en particular en forma libre, en forma pegilada o encapsuladas en eritrocitos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307197.2A EP3187190A1 (en) | 2015-12-31 | 2015-12-31 | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| PCT/EP2017/050006 WO2017114966A1 (en) | 2015-12-31 | 2017-01-02 | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018007933A true MX2018007933A (es) | 2018-08-09 |
| MX393793B MX393793B (es) | 2025-03-24 |
Family
ID=55079994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007933A MX393793B (es) | 2015-12-31 | 2017-01-02 | Composición farmacéutica que comprende asparaginasa y metioninasa para tratar cáncer. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11141468B2 (es) |
| EP (2) | EP3187190A1 (es) |
| JP (1) | JP6966451B2 (es) |
| KR (1) | KR102268259B1 (es) |
| CN (1) | CN108472339B (es) |
| AU (1) | AU2017204678B2 (es) |
| BR (1) | BR112018013227A2 (es) |
| CA (1) | CA3009918C (es) |
| ES (1) | ES2881787T3 (es) |
| IL (1) | IL260278B (es) |
| JO (1) | JO3709B1 (es) |
| MX (1) | MX393793B (es) |
| RU (1) | RU2733389C2 (es) |
| SG (1) | SG11201805311XA (es) |
| WO (1) | WO2017114966A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) * | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| HUE054471T2 (hu) | 2014-04-01 | 2021-09-28 | Rubius Therapeutics Inc | Immunmodulációs módszerek és készítmények |
| EP3187190A1 (en) * | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| HRP20220147T1 (hr) | 2016-01-11 | 2022-04-15 | Rubius Therapeutics, Inc. | Pripravci i postupci povezani s multimodalnim terapijskim staničnim sustavima za indikacije raka |
| US11001826B2 (en) | 2017-10-19 | 2021-05-11 | Anticancer, Inc. | Orally administered composition to lower serum methionine levels and method of use |
| US20220362357A1 (en) | 2018-08-31 | 2022-11-17 | Stichting Radboud Universitair Medisch Centrum | Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof |
| TW202029967A (zh) | 2018-10-26 | 2020-08-16 | 美國德州系統大學評議委員會 | 用於治療用途之經工程改造之靈長目動物胱胺酸/半胱胺酸降解酵素 |
| US20210403571A1 (en) * | 2018-11-15 | 2021-12-30 | Erytech Pharma | Synergistic combinations of methionine depletion agents and immune checkpoint modulators |
| EP4048303A1 (en) | 2019-10-25 | 2022-08-31 | Jazz Pharmaceuticals Ireland Ltd. | Recombinant l-asparaginase |
| WO2021228832A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891704A (en) * | 1992-11-19 | 1999-04-06 | Anticancer, Inc. | Method to produce high levels of methioninase |
| US5715835A (en) * | 1992-11-19 | 1998-02-10 | Anticancer, Inc. | Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions |
| US6017962A (en) * | 1997-02-27 | 2000-01-25 | Board Of Regents, The University Of Texas System | Method of depletion of methionine in plasma and solid tumors and uses thereof |
| AU724448B2 (en) | 1997-03-13 | 2000-09-21 | Shionogi & Co., Ltd. | Process for production of L-Methionine gamma-lyase crystals |
| CN101579362A (zh) * | 1999-10-04 | 2009-11-18 | 维昂药品公司 | 用于将效应分子定向递送至肿瘤的组合物及方法 |
| CA2478338A1 (en) * | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| EP1531823A4 (en) * | 2002-05-10 | 2007-07-18 | Univ Ohio State | FLAVIN N-OXIDE: NEW CANCER AND MEANS TO REMOVE ENTANGERS |
| EP1734972A4 (en) * | 2004-03-29 | 2007-08-22 | Roswell Park Cancer Inst | METHOD FOR THE TREATMENT OF SOLID TUMORS AND LEUKIES THROUGH VITAMIN D COMBINATION THERAPY AND ANTI-CHANGE NUCLEOSIDE ANALOGS |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| US20100284982A1 (en) * | 2007-12-20 | 2010-11-11 | Yang Victor C | Erythrocyte-encapsulated L-asparaginase for enhanced acute lymphoblastic leukemia therapy |
| SG11201405919QA (en) | 2012-03-21 | 2014-10-30 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (aml) |
| US9913822B2 (en) * | 2012-04-04 | 2018-03-13 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and therapeutic agent |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| EP3046550B1 (en) * | 2013-09-17 | 2020-04-15 | The Regents of the University of California | Enzyme-encapsulated nanoparticle platform |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| EP3187190A1 (en) * | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
-
2015
- 2015-12-31 EP EP15307197.2A patent/EP3187190A1/en not_active Withdrawn
-
2016
- 2016-12-27 JO JOP/2016/0276A patent/JO3709B1/ar active
-
2017
- 2017-01-02 CA CA3009918A patent/CA3009918C/en active Active
- 2017-01-02 RU RU2018123666A patent/RU2733389C2/ru active
- 2017-01-02 KR KR1020187018561A patent/KR102268259B1/ko not_active Expired - Fee Related
- 2017-01-02 JP JP2018534048A patent/JP6966451B2/ja not_active Expired - Fee Related
- 2017-01-02 AU AU2017204678A patent/AU2017204678B2/en not_active Ceased
- 2017-01-02 EP EP17700008.0A patent/EP3397272B1/en active Active
- 2017-01-02 US US16/067,398 patent/US11141468B2/en not_active Expired - Fee Related
- 2017-01-02 CN CN201780005554.2A patent/CN108472339B/zh not_active Expired - Fee Related
- 2017-01-02 WO PCT/EP2017/050006 patent/WO2017114966A1/en not_active Ceased
- 2017-01-02 ES ES17700008T patent/ES2881787T3/es active Active
- 2017-01-02 SG SG11201805311XA patent/SG11201805311XA/en unknown
- 2017-01-02 MX MX2018007933A patent/MX393793B/es unknown
- 2017-01-02 BR BR112018013227A patent/BR112018013227A2/pt not_active Application Discontinuation
-
2018
- 2018-06-26 IL IL260278A patent/IL260278B/en unknown
-
2021
- 2021-08-24 US US17/410,485 patent/US20220040272A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1256155A1 (en) | 2019-09-13 |
| AU2017204678B2 (en) | 2021-12-09 |
| JP6966451B2 (ja) | 2021-11-17 |
| US20220040272A1 (en) | 2022-02-10 |
| US11141468B2 (en) | 2021-10-12 |
| CA3009918C (en) | 2024-01-02 |
| WO2017114966A1 (en) | 2017-07-06 |
| RU2733389C2 (ru) | 2020-10-01 |
| EP3397272A1 (en) | 2018-11-07 |
| RU2018123666A3 (es) | 2020-02-26 |
| KR20180097596A (ko) | 2018-08-31 |
| RU2018123666A (ru) | 2019-12-31 |
| SG11201805311XA (en) | 2018-07-30 |
| MX393793B (es) | 2025-03-24 |
| KR102268259B1 (ko) | 2021-06-24 |
| AU2017204678A1 (en) | 2018-07-12 |
| IL260278A (en) | 2018-07-31 |
| JO3709B1 (ar) | 2021-01-31 |
| JP2019500386A (ja) | 2019-01-10 |
| CA3009918A1 (en) | 2017-07-06 |
| IL260278B (en) | 2022-03-01 |
| US20190000941A1 (en) | 2019-01-03 |
| BR112018013227A2 (pt) | 2018-12-04 |
| EP3187190A1 (en) | 2017-07-05 |
| EP3397272B1 (en) | 2021-06-23 |
| CN108472339A (zh) | 2018-08-31 |
| CN108472339B (zh) | 2022-02-15 |
| ES2881787T3 (es) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018007933A (es) | Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina. | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| CL2018002137A1 (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400) | |
| MX2024000348A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| MX2017013590A (es) | Administracion de agente anticaspa soluble en surfactante. | |
| AR097901A1 (es) | Agente beneficioso con partículas de administración | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| PE20211069A1 (es) | Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| AR096893A1 (es) | Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| PE20170392A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| PE20181445A1 (es) | Formulaciones para el tratamiento del cancer de vejiga | |
| ECSP11011552A (es) | Administracion continua de cilengitida en tratamientos contra el cancer | |
| NI201500100A (es) | Mãtodos de tratamiento de la deficiencia de hierro con pirofosfato fãrrico soluble | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2019009190A (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| CL2018002734A1 (es) | Métodos de tratamiento con vitamina d | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2018012285A (es) | Metodos de tratamiento para enfermedades colestasicas y fibroticas. | |
| MX2021005876A (es) | Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama. |